BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16617383)

  • 1. [First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer].
    Lehoczky O; Pulay T
    Magy Onkol; 2006; 50(1):43-6. PubMed ID: 16617383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of docetaxel therapy in patients with relapsed ovarian cancer].
    Lehoczky O; Thurzó L; Bagaméri A; Sárosi Z; Udvary J; Pulay T
    Magy Onkol; 2005; 49(1):71-5. PubMed ID: 15902338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer.
    Niwa Y; Nakanishi T; Kuzuya K; Nawa A; Mizutani S
    Int J Clin Oncol; 2003 Dec; 8(6):343-7. PubMed ID: 14663634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
    Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
    Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer.
    Oishi T; Kigawa J; Fujiwara K; Fujiwara M; Numa F; Aotani E; Katsumata N; Kohno I; Kato H; Terakawa N;
    Gynecol Oncol; 2003 Aug; 90(2):421-4. PubMed ID: 12893211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective weekly docetaxel for recurrent ovarian cancer: A case report.
    Komiyama S; Mizusawa Y; Onouchi M; Takehara K; Suzuki A; Mikami M
    Int J Gynecol Cancer; 2003; 13(5):683-6. PubMed ID: 14675355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
    Kushner DM; Connor JP; Sanchez F; Volk M; Schink JC; Bailey HH; Harris LS; Stewart SL; Fine J; Hartenbach EM;
    Gynecol Oncol; 2007 May; 105(2):358-64. PubMed ID: 17258800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
    Kunos CA; Sill MW; Buekers TE; Walker JL; Schilder JM; Yamada SD; Waggoner SE; Mohiuddin M; Fracasso PM
    Gynecol Oncol; 2011 Feb; 120(2):224-8. PubMed ID: 21075438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
    Guardiola E; Peyrade F; Chaigneau L; Cupissol D; Tchiknavorian X; Bompas E; Madroszyk A; Ronchin P; Schneider M; Bleuze JP; Blay JY; Pivot X
    Eur J Cancer; 2004 Sep; 40(14):2071-6. PubMed ID: 15341981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
    Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
    J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
    Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA
    Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of pegylated liposomal doxorubicin in relapsed ovarian cancer].
    Lehoczky O; Pulay T
    Magy Onkol; 2006; 50(3):261-4. PubMed ID: 17099788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Hitt R; Amador ML; Quintela-Fandino M; Jimeno A; del Val O; Hernando S; Cortes-Funes H
    Cancer; 2006 Jan; 106(1):106-11. PubMed ID: 16329139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
    Miolo G; Bidoli E; Lombardi D; Santeufemia DA; Capobianco G; Dessole F; Scalone S; Spazzapan S; Sorio R; Tabaro G; Veronesi A
    Arch Gynecol Obstet; 2012 Feb; 285(2):499-503. PubMed ID: 21735184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
    J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up.
    Brunsvig PF; Hatlevoll R; Berg R; Lauvvang G; Owre K; Wang M; Aamdal S
    Lung Cancer; 2005 Oct; 50(1):97-105. PubMed ID: 16005105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
    Pokrzywinski R; Secord AA; Havrilesky LJ; Puls LE; Holloway RW; Lewandowski GS; Higgins RV; Nycum LR; Kohler MF; Revicki DA
    Gynecol Oncol; 2011 Dec; 123(3):505-10. PubMed ID: 21945310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.